T-Eco
Microbiome atlas powered by AI, Big Data & Systems Biology.
Unlocking the Oral and Gut Microbiome for Therapeutic Discovery
T-ECO is a comprehensive oral and gut microbiome atlas and designed to enhance the visualization and analysis of microbiome data. By uncovering the mechanisms behind complex and chronic diseases, T-ECO enables researchers to explore microbial interactions, establish cross-talks, identify new therapeutic targets, toxicity and efficacy tests. This platform connects microbiome with drug discovery, providing a structured approach to identifying actionable insights for advanced therapeutic development with high success rates.
Data-Powered Microbiome Research: A Comprehensive Resource
T-ECO provides an extensive microbiome dataset covering 30+ diseases, with over 20 million genes and thousands of bacterial interactions mapped. With availability of more than 50K metagenomics species, our resource offers unprecedented insights into the complex relationships between microbial communities and human health. By integrating large-scale microbiome data, T-ECO provides deeper insights into microbial communities and human health, enabling to uncover novel disease mechanisms and pinpoint key microbial targets for therapeutic and diagnosis advancement.
Smart Prioritization: Confidence-Driven Drug-Target Ranking
T-ECO advances therapeutic discovery by enabling the ranking of predicted microbiome-target interactions based on microbial, host, and drug interactions. This approach allows users to efficiently identify the most promising interventions and assess the microbiome's contribution to pharmacokinetics, even without specialized bioinformatics expertise. For those seeking deeper insights, prioritization can be refined using criteria such as microbial influence on drug efficacy, correlation strength, and disease-specific relevance. This data-driven strategy accelerates breakthroughs by leveraging microbiome intelligence for smarter, more effective treatment selection.
50K+ metagenome species
100K+ bacterial interactions
20M+ genes
Global compositional and functional states of the human gut microbiome in health and disease
We leveraged our microbiome platform to identify novel diagnostic markers for ccRCC, highlighting Enterocloster asparagiformis as a key bacterium. While this marker enables early diagnosis of ccRCC, it also holds potential for therapeutic development. Another case study focuses on Parkinson’s disease (PD), where we have established a strong gut-brain axis connection, linking microbiome composition to both the onset and progression of PD.
Case Study: Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning
We identify PKLR as a key regulator of NAFLD and reposition small-molecule inhibitors through a computational drug discovery pipeline, validating their efficacy in preclinical models.
Learn more about T-ECO